Independent retatrutide approval tracker
Is retatrutide FDA approved?
Not FDA approved
Retatrutide remains an investigational drug. It has not been approved by the FDA or by any other regulator, and no FDA decision date has been announced. Lilly has said it plans to submit a Biologics License Application in Q1 2027. A submission would begin the regulatory process; it would not itself make retatrutide an approved medicine.
- Regulatory status
- Investigational
- Approval date
- None. No FDA decision date exists.
- Planned BLA submission
- Q1 2027 (company projection)
Submission is not approval. Filing a Biologics License Application asks the FDA to begin a review. The FDA can accept it, refuse to file it, approve the drug, or issue a complete response letter instead.What has to happen before approval.
Primary source:Drugs@FDA: FDA-Approved Drugs,U.S. Food and Drug Administration. Checked July 30, 2026.
What this means
“Investigational” is the FDA's own term for a drug being studied under an Investigational New Drug application. It means the drug may be given to people inside authorised clinical trials, and may not be sold or prescribed as a medicine. Retatrutide has been in that category since its first human study in 2019, and it is still there today.
What has changed is the weight of evidence behind it. Lilly has now disclosed positive topline results from five Phase 3 trials and has said it intends to ask the FDA for approval in the first quarter of 2027. That is a meaningful step. It is also, precisely, a plan to ask.
The distance between “the company plans to file” and “you can be prescribed this” is several distinct regulatory events, none of which has happened.Each one is set out here.
Next expected milestone
Planned regulatory submission window
Lilly’s stated Q1 2027 filing window opensJanuary 1, 2027
This tracks a stated filing window, not an FDA approval date.
- Window
- Q1 2027
- Set by
- Eli Lilly, not the FDA
- Is this an approval date?
- No
Lilly has publicly stated a planned submission window. A submission is the start of FDA review, not an approval, and the window is the company's own projection rather than a date set by the FDA.
“Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.”
Eli Lilly and Company, July 23, 2026
What is confirmed, and what is not
Confirmed
- Retatrutide is investigational. It has no approval record in Drugs@FDA.
- Lilly has disclosed positive topline results from five Phase 3 studies.
- One of those five, TRANSCEND-T2D-1, has been published in a peer-reviewed journal.
- Lilly has stated it plans to submit a BLA to the FDA in Q1 2027.
Not confirmed
- That a submission has been made — as of the last check, it has not.
- Any FDA approval date.
- Any FDA decision (PDUFA) date.
- A commercial launch date.
- A U.S. brand name.
- A U.S. list price.
- Insurance or Medicare coverage.
Regulatory timeline
What has happened, and what has not
What has not happened yetNot yet occurred
Q1 2027
Planned BLA submission to the FDA
The window Lilly has stated for filing a Biologics License Application. This is the company's own projection. It has not happened, and the FDA has not set or endorsed this date.
Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials · Eli Lilly and Company
No date set
FDA decides whether to accept the application
After a submission, the FDA has roughly 60 days to decide whether the application is complete enough to review. Acceptance is not approval — it means the review clock starts and a decision date is assigned.
Drugs@FDA: FDA-Approved Drugs · U.S. Food and Drug Administration
No date set
FDA decision date (PDUFA date) set
The target date by which the FDA aims to complete its review. No such date exists for retatrutide, and none can exist before an application is filed and accepted.
Drugs@FDA: FDA-Approved Drugs · U.S. Food and Drug Administration
No date set
FDA decision: approval or complete response
The review ends in either an approval or a Complete Response Letter setting out what would have to change. Neither outcome is guaranteed, and Lilly's own disclaimer states there is no guarantee that retatrutide will receive regulatory approval.
Drugs@FDA: FDA-Approved Drugs · U.S. Food and Drug Administration
Verified recordOccurred
Lilly states a Q1 2027 BLA submission plan
In the same release, Lilly says it is completing the Chemistry, Manufacturing and Controls data package and “plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.” Stating a plan is a corporate disclosure, not a regulatory step — nothing has been filed with the FDA.
Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials · Eli Lilly and Company
TRIUMPH-2 and TRIUMPH-3 topline results
Lilly reports positive topline results from two more pivotal Phase 3 trials, bringing the number of Phase 3 studies it describes as positive to five.
Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials · Eli Lilly and Company
First Phase 3 peer-reviewed publication
TRANSCEND-T2D-1 is published in The Lancet — as of the last verification date, the only Phase 3 retatrutide trial to have been through external peer review.
TRIUMPH-1 topline results
Lilly reports positive topline results from its pivotal Phase 3 obesity trial, including a pre-specified 104-week extension in participants with a BMI of 35 or above.
Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial · Eli Lilly and Company
TRANSCEND-T2D-1 topline results
Lilly reports positive topline results in adults with type 2 diabetes inadequately controlled on diet and exercise alone.
Lilly's triple agonist retatrutide demonstrated significant A1C and weight reductions in Phase 3 type 2 diabetes trial · Eli Lilly and Company
Phase 3 programme
The evidence base, in numbers
- Phase 3 trials registered
- 14
- Completed
- 5
- Results disclosed by Lilly
- 5
- Peer-reviewed publications
- 1
Four of the five disclosed readouts are topline results reported by Lilly and have not yet been fully evaluated in a peer-reviewed publication. Across all14 registered Phase 3 studies, planned or actual enrolment totals roughly 25,364 participants — a figure dominated by TRIUMPH-Outcomes, which does not complete until 2029.
The path from here
What must happen before retatrutide could be approved
- 01
Lilly files a Biologics License Application
Planned for Q1 2027. Has not happened. This is the company asking the FDA to review the drug, and it includes the manufacturing data package Lilly says it is still completing.
- 02
The FDA decides whether to accept the filing
Roughly 60 days after submission, the agency decides whether the application is complete enough to review. It can refuse to file it. Acceptance is not approval — it means the review has begun.
- 03
A decision date is set
On acceptance, the FDA assigns a target date under the Prescription Drug User Fee Act — the PDUFA date. No PDUFA date exists for retatrutide, and none can until a filing is accepted.
- 04
The FDA reviews, and decides
The review ends in an approval or a Complete Response Letter setting out what would have to change. Advisory committee meetings and inspections may happen along the way. Neither outcome is guaranteed.
Definitions of BLA, filing acceptance, PDUFA date and Complete Response Letter are on the FDA approval status page.
Latest verified updates
What changed recently
TRIUMPH-2 and TRIUMPH-3 report positive topline results
Lilly reported that both trials met their primary endpoint. With these two readouts, the company describes five Phase 3 retatrutide studies as positive. The cardiovascular event data in TRIUMPH-3 did not establish a benefit.
What did not change: None of these results has been through peer review. None of them changes the regulatory status. A trial meeting its endpoint is evidence for an application, not a substitute for one.
Source:Eli Lilly and Company
Lilly states it plans to submit retatrutide to the FDA in Q1 2027
Eli Lilly said it is completing the manufacturing data package for a Biologics License Application and plans to file with the FDA in the first quarter of 2027. Nothing has been submitted yet, and the FDA has not set any date.
What did not change: Retatrutide is still investigational. Nothing has been filed with the FDA, the FDA has not accepted anything, there is no PDUFA date, and there is no approval. The drug cannot be prescribed.
Source:Eli Lilly and Company
First Phase 3 retatrutide trial appears in a peer-reviewed journal
TRANSCEND-T2D-1 was published in The Lancet — the first and, so far, only Phase 3 retatrutide trial to be externally peer reviewed rather than reported only by the sponsor.
What did not change: The four TRIUMPH readouts remain unpublished. The regulatory status is unaffected — journals do not approve drugs.
Source:The Lancet
Background
What retatrutide is
Retatrutide, also known by its development code LY3437943, is an investigational once-weekly injectable being developed by Eli Lilly and Company. It is a single molecule that activates three receptors: GIP, GLP-1 and glucagon. Drugs already on the market act on one or two of these — which is why retatrutide is usually described as a triple agonist, and why its trial results have drawn the attention they have.
Lilly is studying it in obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic kidney disease, cardiovascular outcomes and liver disease. That breadth is the strategy: a single molecule with several approvable indications.
This site does not describe how retatrutide is dosed or used. It is not an approved medicine, there is no approved label, and there is no responsible way to publish dosing guidance for a drug that no one can legally be prescribed.
Right now
Can you get it?
Not as a prescription. There is no approved retatrutide product, so no pharmacy can legally dispense one and no clinician can prescribe it as a medicine.
The routes that exist are Lilly's clinical trials, and a pre-approval expanded access record the company has listed on ClinicalTrials.gov with a status of Available. Expanded access is a regulated pathway involving the sponsor, a treating physician and the FDA. It is not a prescription and not a commercial supply.
Substances sold online as “retatrutide”, including those labelled for research use only, are not FDA-approved Lilly medicines. The FDA has issued warning letters describing such products as unapproved new drugs.
Email alerts
Get the next verified retatrutide update
One email when a major regulatory milestone is verified against a primary source. Not a newsletter, not a digest, and never a promotion for something sold as retatrutide.
How this is verified
Sources and method
Every status on this site is checked against primary sources in a fixed order: the FDA first, then ClinicalTrials.gov, then Lilly's own disclosures, then the peer-reviewed literature. Secondary coverage is used to find out that something happened, never to establish what happened.
Approval status is checked against Drugs@FDA and the openFDA drug application API — the same records that would show an approval the moment one existed. Trial status comes from the registry entries the sponsor is legally required to keep current. Company statements are quoted from the release rather than paraphrased.
Where a figure differs between sources, both are reported. Lilly's press release for TRIUMPH-1 says 2,339 participants were randomised; the registry records 2,335. We show the registry figure and note the company's, rather than quietly picking one.
The full source catalogue ·Editorial policy ·Corrections log
Common questions
Retatrutide status FAQ
Is retatrutide FDA approved?
No. Retatrutide is investigational and has no approval record in Drugs@FDA. It has not been approved by the FDA or by any other regulator.
When will retatrutide be approved by the FDA?
There is no answer to this, because no application has been filed. Lilly has said it plans to submit a Biologics License Application in Q1 2027. The FDA has not set any decision date, and approval is not guaranteed.
Has Lilly submitted retatrutide to the FDA?
Not as of the last verification date. Lilly has stated a plan to submit in Q1 2027, which is a company projection rather than a completed filing.
Can I get retatrutide now?
Not as a prescription medicine — no approved retatrutide product exists. The routes Lilly describes are its clinical trials and a listed pre-approval expanded access record. Products sold online as “retatrutide” are not FDA-approved Lilly medicines, and the FDA has described them as unapproved new drugs.
How much will retatrutide cost?
No official U.S. list price has been announced. A price cannot exist for a product that has not been approved, and any figure circulating now is speculation.
What is the next regulatory milestone?
The planned Q1 2027 Biologics License Application submission. If that happens, the next step would be the FDA deciding whether to accept the application for review, which typically takes about 60 days.
Independence
Retatrutide Status is an independent tracker. It is not affiliated with Eli Lilly and Company, the U.S. Food and Drug Administration, or any regulatory agency.
It does not sell, supply, or facilitate access to any drug, and it carries no affiliate links to sellers of research chemicals. Nothing here is medical advice. Retatrutide is investigational and is not approved for use outside authorised clinical research.Full medical disclaimer.
Want to know when this changes?One email when the FDA status actually moves.